Immunohistochemical assays for programmed cell death ligand 1 (PD-L1) expression in non–small cell lung cancer (NSCLC) are either required or recommended to guide therapy with immune checkpoint inhibitors. Four commercially available immunohistochemical assays are currently available as either complimentary or companion diagnostic assay for their counterpart therapy. Harmonization or…
It’s difficult to imagine starting a cancer treatment path for a patient without first reviewing their molecular test results. This means getting the comprehensive story…
An abstract is unavailable.
An abstract is unavailable.
An abstract is unavailable.
An abstract is unavailable.
An abstract is unavailable.
